ProPhase Labs, Inc.

PRPHNASDAQHealthcare● Active

$0.10

$-0.01(-9.09%)

Market Cap$473701

P/E Ratio—

52W High$6.7

52W Low$0.07

Avg Volume157K

Open$0.09

Beta0.07

Overview

ProPhase Labs, Inc. (PRPH) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PRPH · free cash flow · updated Jun 9, 2026

Core FCF metrics

PRPH · FCF · TTM · margin & CAGR

Free cash flow was −$8.9M for FY2025 (fiscal year ending 2025-12-31), up 51.5% year-over-year The FCF margin was -205.8%.

FY2025 Free Cash Flow−$8.9M▲ +51.5% YoY

Trailing 12M (TTM)−$7.7Mtrailing 4 quarters sum

FCF Margin-205.8%−$8.9M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PRPH · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$8.3M(0M)−$8.9M▲ +51.5%-205.8%

FY2024−$17.5M(1M)−$18.4M▼ 27.2%-272.4%

FY2023−$11.3M(3M)−$14.5M▼ 158.9%-32.7%

FY2022$28.6M(4M)$24.6M▲ +238.0%20.1%

FY2021−$13.6M(4M)−$17.9M▼ 317.0%-22.6%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PRPH · P/FCF · FCF yield · FCF per share

ProPhase Labs, Inc. (PRPH) reported negative free cash flow of −$0.01B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

PRPH · cash flow statement · operating / investing / financing

For FY2025, ProPhase Labs, Inc. generated −$8.3M in operating cash flow and spent 0M in capital expenditures, yielding −$8.9M in free cash flow.

Operating Activities

−$8.3M

Cash from core business operations

2025-12-31

Investing Activities

+$0.9M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$6.8M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$8.3M) − |CapEx| (0M) = FCF (−$8.9M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PRPH vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

ProPhase Labs, Inc.YOU

PRPH

−$8.9M+51.5%-205.8%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

ProPhase Labs, Inc. (PRPH) reported free cash flow of −$8.9M for FY2025 (fiscal year ending 2025-12-31), up 51.5% year-over-year. The FCF margin was -205.8%.

Based on available data, ProPhase Labs, Inc. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $24.6M in FY2022.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PRPH free cash flow · 8 questions

ProPhase Labs, Inc. free cash flow was −$8.9M for FY2025, up 51.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$7.7M.

PRPH free cash flowPRPH FCFPRPH FCF 2025PRPH free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · ProPhase Labs, Inc. · ProPhase Labs, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026